Very early researchUnknownNCT02817945What this trial is testingDual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingWho this might be right forLung CancerNeuroendocrine Neoplasm Peking Union Medical College Hospital 100
Very early researchLooking for participantsNCT06632860What this trial is testingA Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive TumorsWho this might be right forIodine-resistant Thyroid CancerMeningiomaNETs Peking Union Medical College Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06955169What this trial is testingComparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentWho this might be right forIntracranial Meningioma RTOG Foundation, Inc. 130
Very early researchLooking for participantsNCT06632873What this trial is testing177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive TumorsWho this might be right forSSTR2 and Integrin αVβ3 Positive Tumors Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT04997317What this trial is testingTreatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotideWho this might be right forMeningioma University Hospital, Basel, Switzerland 18
Testing effectiveness (Phase 2)Looking for participantsNCT06982300What this trial is testingSSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPCWho this might be right forNasopharyngeal Carcinoma (NPC) University Medical Center Groningen 10
Very early researchStudy completedNCT05871320What this trial is testingNovel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine NeoplasmsWho this might be right forNeuroendocrine Tumors Jagiellonian University 10
Early research (Phase 1)Active Not RecruitingNCT05249114What this trial is testingStudy of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors Providence Health & Services 6
Not applicableLooking for participantsNCT05873777What this trial is testing68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDGWho this might be right forSSTR2FAPPositron-Emission Tomography The First Affiliated Hospital of Xiamen University 30
Testing effectiveness (Phase 2)Ended earlyNCT03773133What this trial is testingEvaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)Who this might be right forSmall Cell Lung Cancer and Breast Cancer Ipsen 9
Very early researchLooking for participantsNCT07301801What this trial is testingClinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant TumorsWho this might be right forMalignant TumorsSSTR2PET Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Testing effectiveness (Phase 2)Looking for participantsNCT07284589What this trial is testingUltralow Dose PET Imaging of SSTR2 Radiotracer UptakeWho this might be right forHealthy (Controls)Healthy VolunteersNeuroendocrine (NE) Tumors Akiva Mintz 200
Testing effectiveness (Phase 2)Ended earlyNCT06939036What this trial is testingStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )Who this might be right forSmall Cell Lung Cancer Extensive StageMerkel Cell Carcinoma Ariceum Therapeutics GmbH 2
Testing effectiveness (Phase 2)Looking for participantsNCT07129252What this trial is testingInvestigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsWho this might be right forSST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm Crinetics Pharmaceuticals Inc. 150
Testing effectiveness (Phase 2)WithdrawnNCT04298541What this trial is testingDirect Comparison of Ga-68-DOTATATE and Ga-68-DOTATOCWho this might be right forMeningioma Weill Medical College of Cornell University
Testing effectiveness (Phase 2)Ended earlyNCT03697551What this trial is testingDefine the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerWho this might be right forBreast Cancer Ipsen 4
Testing effectiveness (Phase 2)Looking for participantsNCT05636618What this trial is testingTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsWho this might be right forNeuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more Perspective Therapeutics 300
Testing effectiveness (Phase 2)Study completedNCT05410743What this trial is testingEvaluation of 177Lu-TATE-EB-01(LNC1010)in SSTR2-positive TumorsWho this might be right forSSTR2-positive Tumors The First Affiliated Hospital of Xiamen University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03454763What this trial is testingOptimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive TumorsWho this might be right forNeuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 618
Testing effectiveness (Phase 2)Looking for participantsNCT06456359What this trial is testingPasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorWho this might be right forDesmoplastic Small Round Cell TumorSynovial Sarcoma University Hospital Heidelberg 28